双蚁复方感冒灵颗粒在此次评选中脱颖而出，成功荣登"2024-2025家庭常备药上榜品牌"感冒药榜单。 此次双蚁复方感冒灵颗粒的入选，不仅是对其产品品质与市场口碑的高度认可，也体现了广大消费者对 其疗效与安全性的信赖。作为家庭药箱中的常备良药，双蚁复方感冒灵颗粒将继续守护万千家庭的健康 日常，为感冒防治提供值得信赖的贴心选择。 此次获奖恰逢流感高发时节，让这份认可更显意义非常。双蚁药业温馨提示您，气温变化较大，请及时 添衣，注意防护。愿双蚁复方感冒灵颗粒常伴左右，为您和家人的健康添一份安心守护。 11月18日，由家庭医生在线主办的"2024-2025家庭常备药、家庭常备营养食品/保健品、家庭常备医疗 器械及消毒用品上榜品牌"活动颁奖典礼在南京隆重举行。 本届评选设立三大子榜单，涵盖家庭常备药、营养食品/保健品、医疗器械及消毒用品三大类别。其 中，"家庭常备药"涵盖感冒用药、妇科疾病、慢病管理、儿科用药、外用止痛等34个细分品类；"家庭 常备营养食品/保健品"包括缓解视疲劳、增加骨密度、睡眠情绪营养等7大类；"家庭常备医疗器械及消 毒用品"则覆盖头皮敷料、疤痕凝胶、消毒用品等6大品类。三大榜单共计130个品牌上榜 ...

Core Insights - Kefu Medical reported a strong performance in Q3 2025, achieving a revenue of 902 million yuan, a year-on-year increase of 30.72%, and a net profit attributable to shareholders of 92.83 million yuan, up 38.68% year-on-year [1] - The company is accelerating its international expansion by submitting a listing application to the Hong Kong Stock Exchange, aiming to become a dual-listed company, which will enhance its global financing channels and brand influence [1][2] - Kefu Medical is focusing on a dual-driven strategy of "product innovation + channel upgrade," with its core categories showing steady growth, ranking second among home medical device companies in China, with rehabilitation aids ranked first [1][2] Financial Performance - In Q3 2025, Kefu Medical achieved a net profit of 92.83 million yuan, reflecting a 38.68% increase year-on-year [1] - The company's net profit excluding non-recurring items reached 85.80 million yuan, marking a significant year-on-year growth of 62.68% [1] Product Innovation - Kefu Medical has increased its R&D investment, launching new products such as portable ventilators, dual glucose and uric acid test strips, a new generation of bone conduction hearing aids, and tunnel-type blood pressure monitors, enhancing its "home health management" product matrix [1][2] - The new generation bone conduction hearing aid developed in collaboration with Tencent has improved voice clarity and intelligibility by 85% in complex noise environments, utilizing deep learning acoustic scene recognition technology [2] International Expansion - The funds raised from the Hong Kong listing will primarily be used for global brand building, overseas channel expansion, and innovation R&D, strengthening the company's international operational capabilities [2] - The move to list in Hong Kong is expected to optimize the company's capital structure and enhance its competitiveness and brand strength in the global home medical device market [2] Industry Outlook - The home medical device industry is experiencing structural growth opportunities due to the "Healthy China 2030" strategy and the aging population trend [2] - Kefu Medical aims to leverage its full industry chain layout and brand advantages to achieve high-quality growth in both domestic and international markets [2]